Halozyme Therapeutics Inc (HALO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.00B
Last updated: Nov 17, 2026 at 4:37 PM ET
Halozyme Therapeutics Inc (HALO) Statistics
Halozyme Therapeutics (HALO) has a market cap of $11.00B and an enterprise value of $13.22B. Revenue grew 45.03% over the last 12 months from the 12 months before. Its return on invested capital of 15.84% compares with a 1.77% median across 6 similar companies.
Total Valuation
Enterprise value is 20.18% above the market cap, as debt exceeds cash.
| Market Cap | $11.00B |
|---|---|
| Enterprise Value | $13.22B |
| Latest price (Nov 17, 2026) | $95.97 |
Key Dates
The next earnings report is expected on Jan 26, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Jan 26, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 6.1x. Its year-end P/E ranged from 11.3x to 53.3x from 2017 to 2025.
| P/E Ratio | 17.7x |
|---|---|
| Forward P/E | 10.6x |
| P/S Ratio | 6.1x |
| Forward P/S | 5.8x |
| P/FCF Ratio | 12.3x |
| P/OCF Ratio | 12.2x |
| PEG Ratio | 3.1 |
Enterprise Valuation
Counting debt and cash, the company is valued at 16.0x EBITDA and 14.8x free cash flow.
| EV / Earnings | 27.2x |
|---|---|
| EV / Sales | 7.3x |
| EV / EBITDA | 16.0x |
| EV / EBIT | 19.4x |
| EV / FCF | 14.8x |
Price Statistics
The stock is up 37.04% over 52 weeks and trades 15.85% below its 50-day average.
| Beta (1Y) | 0.62 |
|---|---|
| 52-Week Change | +37.04% |
| 1-Month Change | -21.66% |
| 3-Month Change | -10.83% |
| 6-Month Change | +39.63% |
| 5-Year Change | +243.87% |
| 10-Year Change | +1416.92% |
| Total Return (1Y) | +37.04% |
| Total Return (3Y CAGR) | +33.94% |
| Total Return (5Y CAGR) | +22.09% |
| Return vs SPY (1Y) | +25.35% |
| Max Drawdown (1Y) | -26.84% |
| Max Drawdown (3Y) | -33.92% |
| Sharpe Ratio (1Y) | 0.77 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $114.04 |
| 200-Day Average | $85.66 |
| 52-Week Range | $61.23 to $134.00 |
| RSI (14 Days) | 23.4 |
| Average Volume (20 Days) | 2.36M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.88x current liabilities.
| Current Ratio | 3.88x |
|---|---|
| Quick Ratio | 3.60x |
| Debt / EBITDA | 3.97x |
| Debt / FCF | 3.67x |
| Interest Coverage | 24.40x |
Returns and Efficiency
Return on invested capital is 15.84% over the last 12 months, against a 5-year average of 18.00%.
| Return on Assets (ROA) | 13.98% |
|---|---|
| Return on Invested Capital (ROIC) | 15.84% |
| Return on Capital Employed (ROCE) | 22.79% |
| ROE (5Y Average) | 286.15% |
| ROA (5Y Average) | 19.55% |
| ROIC (5Y Average) | 18.00% |
| Asset Turnover | 0.63x |
| Inventory Turnover | 2.37x |
| Receivables Turnover | 3.67x |
| Cash Conversion Cycle | 221 days |
Taxes
Income tax took 25.89% of pretax income over the last 12 months.
| Income Tax (TTM) | $169.59M |
|---|---|
| Effective Tax Rate | 25.89% |
Scores
HALO has an Altman Z-Score of 3.47, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.47 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $1.80B over the last 12 months.
| Revenue | $1.80B |
|---|---|
| Revenue Growth (YoY) | +45.03% |
| Gross Profit | $1.48B |
| Operating Income | $674.25M |
| Pretax Income | $655.01M |
| Net Income | $485.42M |
| EBITDA | $818.97M |
| EBIT | $683.00M |
| Reported EPS (TTM) | $5.42 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $1.03B |
|---|---|
| Total Debt | $3.25B |
| Net Debt | $2.22B |
| Net Debt Per Share | $19.51 |
| Working Capital | $1.37B |
| Shareholder Equity | -$55.24M |
| Tangible Book Value | -$1.53B |
| Total Assets | $3.47B |
| Total Liabilities | $3.53B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $12.39M of capital spending, operating cash flow left $885.88M of free cash flow.
| Operating Cash Flow | $898.27M |
|---|---|
| Capital Expenditures | $12.39M |
| Free Cash Flow | $885.88M |
| FCF Per Share | $7.81 |
| Depreciation and Amortization | $135.97M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 37.41%, against a 5-year average of 46.27%.
| Gross Margin | 82.27% |
|---|---|
| Operating Margin | 37.41% |
| Pretax Margin | 36.34% |
| Net Margin | 26.93% |
| EBITDA Margin | 45.44% |
| EBIT Margin | 37.89% |
| FCF Margin | 49.15% |
| Gross Margin (5Y Average) | 81.05% |
| Operating Margin (5Y Average) | 46.27% |
| Net Margin (5Y Average) | 44.37% |
Growth
Revenue grew 28.38% a year over 3 years, and EPS 22.99% a year.
| Revenue Growth (3Y CAGR) | +28.38% |
|---|---|
| Revenue Growth (5Y CAGR) | +39.16% |
| EPS Growth (3Y CAGR) | +22.99% |
| EPS Growth (5Y CAGR) | +35.63% |
| FCF Growth (3Y CAGR) | +39.92% |
| FCF Growth (5Y CAGR) | +64.85% |
| Operating Income Growth (3Y CAGR) | +20.58% |
| Book Value Per Share Growth (2Y CAGR) | -19.46% |
Dividends and Yields
HALO does not pay a dividend. Its free cash flow yield is 8.11%.
| Earnings Yield | 5.65% |
|---|---|
| FCF Yield | 8.11% |
| Buyback Yield | 0.37% |
| Shareholder Yield | 0.37% |
Peer Position
Against 7 similar companies, HALO has the lowest P/E.
P/E RatioPeer median 39.5x
P/S RatioPeer median 13.1x
ROICPeer median 1.77%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +25.96%
| P/E Ratio | 17.7x vs 39.5x median |
|---|---|
| P/S Ratio | 6.1x vs 13.1x median |
| ROIC | 15.84% vs 1.77% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +45.03% vs +25.96% median |
Analyst Forecast
Consensus estimates put revenue growth at 24.96% and EPS growth at 60.15% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +24.96% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +60.15% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HALO
What is HALO's market cap?
Halozyme Therapeutics has a market cap of $11.00B. Its enterprise value, which adds debt and subtracts cash, is $13.22B.
What is HALO's P/E ratio?
Halozyme Therapeutics has a trailing P/E ratio of 17.7x and a forward P/E of 10.6x.
How many shares of HALO are outstanding?
Halozyme Therapeutics has 113.80M shares outstanding. The count is down 2.92% from a year earlier.
Does HALO pay a dividend?
No. Halozyme Therapeutics does not pay a dividend.
How much debt does HALO have?
Halozyme Therapeutics has $3.25B of total debt and $1.03B of cash and equivalents, a net debt position of $2.22B.
HALO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors